培美曲塞联合卡铂治疗晚期非小细胞肺癌的近远期疗效

Short-term and long-term curative effect of pemetrexed combined with carboplatin on advanced NSCLC

目的观察培美曲塞联合卡铂治疗晚期非小细胞肺癌(NSCLC)的近远期疗效。方法选取2015年6月至2017年9月在我院治疗的NSCLC患者92例,采用随机法将其分为观察组和对照组,每组46例。对照组给予吉西他滨联合卡铂治疗,观察组给予卡铂与培美曲塞联合治疗。比较两组治疗总有效率(RR);比较两组治疗前后肺癌症状评分量表(LCSS)评分;比较两组1年生存率、病死率及复发率;比较两组治疗期间不良反应发生情况。结果观察组RR高于对照组(P<0.05);观察组治疗后LCSS评分高于对照组(P<0.05);观察组1年生存率高于对照组,病死率及复发率低于对照组(P<0.05);观察组骨髓抑制、胃肠道反应发生率低于对照组(P<0.05)。结论应用培美曲塞联合卡铂治疗晚期NSCLC有效率高,可提高1年生存率,改善其生活质量,降低不良反应发生率。

Objective To observe the short-term and long-term curative effect of pemetrexed combined with carboplatin on advanced non-small cell lung cancer(NSCLC).Methods A total of 92 NSCLC patients treated in the hospital from June 2015 to September 2017 were selected and divided into observation group and control group by random,46 cases in each group.Control group was given gemcitabine combined with carboplatin,while observation group received carboplatin combined with pemetrexed.The total response rate(RR)of treatment,scores of Lung Cancer Symptom Scale(LCSS)before and after treatment,1-year survival rate,mortality and recurrence rate,and the occurrence of toxic and side effects during treatment were compared between two groups.Results RR in observation group was higher than that in control group(P<0.05).After treatment,LCSS scores in observation group were higher than those in control group(P<0.05).The 1-year survival rate in observation group was higher than that in control group,while the mortality and recurrence rates were lower than those in control group(P<0.05).The incidences of bone marrow suppression and gastrointestinal reactions in observation group were lower than those in control group(P<0.05).Conclusion The application of pemetrexed combined with carboplatin in the treatment of advanced NSCLC has a high efficiency,which can increase the 1-year survival rate,improve the quality of life,and reduce the incidence of toxic and side effects.